NCT00490906View on ClinicalTrials.gov

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

December 31, 2012

Conditions
Multiple SclerosisLow Bone Density
Interventions
DRUG

Copaxone

20 mg, subcutaneous injections, taken daily

DRUG

Interferon-beta 1a

30 mcg injected intramuscularly, once weekly

DRUG

Interferon-beta 1b

.25 mg/day, taken every other day, subcutaneous injections

Trial Locations (2)

66160

General Clinical Research Center, Kansas City

University of Kansas Medical Center, Kansas City

All Listed Sponsors
collaborator

Kansas City Area Life Sciences Institute, Inc.

OTHER

lead

Nancy Hammond, MD

OTHER

NCT00490906 - Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis | Biotech Hunter | Biotech Hunter